Literature DB >> 11371996

New drug development in the United States from 1963 to 1999.

J A Dimasi1.   

Abstract

Mesh：

Substances：

Year:  2001        PMID： 11371996     DOI： 10.1067/mcp.2001.115132

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  43 in total

1.  The value of improving the productivity of the drug development process: faster times and better decisions.

Authors:  Joseph A DiMasi
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

2.  A virtual national laboratory for reengineering clinical translational science.

Authors:  David M Dilts; Daniel Rosenblum; William M Trochim
Journal:  Sci Transl Med       Date:  2012-01-25       Impact factor: 17.956

3.  The economics of follow-on drug research and development: trends in entry rates and the timing of development.

Authors:  Joseph A DiMasi; Cherie Paquette
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 4.  The influence of market exclusivity on drug availability and medical innovations.

Authors:  Gregory J Glover
Journal:  AAPS J       Date:  2007-08-03       Impact factor: 4.009

5.  Adverse event detection in drug development: recommendations and obligations beyond phase 3.

Authors:  Jesse A Berlin; Susan C Glasser; Susan S Ellenberg
Journal:  Am J Public Health       Date:  2008-06-12       Impact factor: 9.308

Review 6.  Exploiting drug-disease relationships for computational drug repositioning.

Authors:  Joel T Dudley; Tarangini Deshpande; Atul J Butte
Journal:  Brief Bioinform       Date:  2011-06-20       Impact factor: 11.622

Review 7.  Mechanistic systems modeling to guide drug discovery and development.

Authors:  Brian J Schmidt; Jason A Papin; Cynthia J Musante
Journal:  Drug Discov Today       Date:  2012-09-19       Impact factor: 7.851

Review 8.  ["Me-too drugs" and the concept of a class effect].

Authors:  Brigitte Blöchl-Daum
Journal:  Wien Med Wochenschr       Date:  2006-09

Review 9.  How multi-organ microdevices can help foster drug development.

Authors:  Mandy B Esch; Alec S T Smith; Jean-Matthieu Prot; Carlota Oleaga; James J Hickman; Michael L Shuler
Journal:  Adv Drug Deliv Rev       Date:  2014-01-09       Impact factor: 15.470

10.  Screening a mushroom extract library for activity against Acinetobacter baumannii and Burkholderia cepacia and the identification of a compound with anti-Burkholderia activity.

Authors:  William R Schwan; Craig Dunek; Michael Gebhardt; Kathleen Engelbrecht; Tiffany Klett; Aaron Monte; Joseph Toce; Marc Rott; Thomas J Volk; John J LiPuma; Xue-Ting Liu; Ronald McKelvey
Journal:  Ann Clin Microbiol Antimicrob       Date:  2010-01-21       Impact factor: 3.944
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.